|Time Commitment:||3 hours over 5 weeks|
|Target Professions:||DO, MD, Nurse, Nurse Practitioner, Physician Assistant|
|Target Specialties:||Family Medicine, Internal Medicine, Oncology, Pathology, Pulmonary/Respiratory Physician|
|Credits Available:||3.00 AMA PRA Category 1 Credit™|
Are you interested in staying up-to-date with the latest guideline recommendations for biomarker identification and application in Non-Small Cell Lung Cancer (NSCLC)? Our interactive program is here to help! With this program, you'll be able to select personalized treatment pathways based on the tumor profile, while incorporating the latest scientific advances applicable to a broad range of patients with PD-L1–positive NSCLC. Get ready to make informed decisions about the best treatment options for NSCLC.
This module presents current guideline recommendations for biomarker testing and the impact of testing on treatment selection in NSCLC.
This module summarizes guideline recommendations and analyzes newer data to further fine-tune treatment protocols.
This discussion focuses on review of key concepts from the self-study modules and group member questions.
This discussion focuses on review of the case study in addition to the case of Mrs. Jones. Action plans will also be presented as we reflect on how our practice will change as a result of this CME activity.
Meet Mr. Walters, a 65-year-old male with newly diagnosed adenocarcinoma
In light of the information reviewed and discussed during this program, can you share an action plan that you will implement to improve the outcomes for your patients with Metastatic Non-Small Cell Lung Cancer.